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a B s t R a C t
Lichen striatus is an uncommon acquired linear inflammatory skin disorder, that 
preferentially occurs in children. We report a 15-year-old girl with a 16-month his-
tory of lichen striatus. Topical application of imiquimod 5% cream twice-daily under 
occlusion led to resolution of the intense pruritus within 6 days of treatment and to 
complete remission of the cutaneous lesions after 5 weeks of treatment. The patient 
experienced no local or systemic side effects. She has been followed-up for 13 months 
and revealed no evidence of recurrence. Topical imiquimod may be an effective and 
safe alternative treatment for recalcitrant lichen striatus.
I n t R o d u C t I o n
Lichen striatus (LS) is an uncommon acquired inflammatory skin disorder with 
linear distribution along Blaschko’s lines, that preferentially occurs in children.1 Since 
LS is a benign, self-limited dermatosis spontaneously resolving in 6-12 months, its 
treatment is necessary only in patients with widespread or pruriginous lesions, no ten-
dency to resolve and with frequent relapses. We report herein a patient with persistent 
lichen striatus, who showed complete remission of her skin lesions after 5 weeks of 
treatment with imiquimod 5% cream.
C a s e  R e p o R t
A 15-year-old Caucasian girl presented with a 16-month history of intensely pruritic 
skin lesions on her left thigh. The eruption had been diagnosed as lichen striatus and 
was left untreated, but since its expected spontaneous resolution was not observed 
within 16 months, the patient was referred to our Department of Dermatology. On 
physical examination, erythematosquamous and verrucous papules were seen, that 
clustered in an focally interrupted linear plaque (15 cm × 2 cm) extending on the 
posterior aspect of her left thigh along Blaschko’s lines (Fig. 1A).
Histological examination of a biopsy obtained from the lesional skin revealed 
hyperkeratosis, orthokeratosis, focal parakeratosis and hypergranulosis, spongiosis, 
necrotic keratinocytes, invasion of lymphocytes into the epidermis and a moderately 
dense perivascular and perifollicular lymphohistiocytic infiltrate (Fig. 2). In view of 
the clinical and the histological features2 the diagnosis of LS was made. Subsequent 
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to a thorough explanation of the safety profile of imiquimod 
5% cream, the patient’s parents gave their written informed 
consent and were instructed to apply this compound to the 
lesions twice daily under occlusion.
At six days after the onset of treatment the lesions became 
edematous, their color changed into violet and there was a 
resolution of pruritus, showing a progressive improvement 
thereafter (Fig. 1B). A complete remission of the lesions was 
achieved after 5 weeks of continuous treatment (Fig. 1C). The 
patient experienced no local or systemic side effects; she has 
been followed-up for 13 months and revealed no evidence of 
recurrence.
d I s C u s s I o n
Imiquimod is a topically applicable Toll-like receptor-7/8 
(TLR-7/8) agonist that stimulates the cutaneous innate and the 
cellular arm of adaptive immune response and exerts distinct 
antiviral, antitumor and immunoregulatory effects.3,4 This 
compound is currently regarded as an efficient and safe topical 
agent for the immunotherapy of a variety of cutaneous infec-
tions, neoplasms and inflammatory disorders, most of which 
previously represented frustrating therapeutic problems.5-8
The exact immunomodulatory mechanisms underlying 
the impressive therapeutic effect of topical imiquimod in LS, 
reported for the first time in this study, remain to be elucidated. 
It may be suggested, however, that imiquimod-induced stimula-
tion of TLR7- and TLR8-mediated signaling pathways leading 
to enhanced transcription and local release of pro-inflamma-
tory cytokines, chemokines and other mediators9 may interfere 
with the T cell-mediated inflammatory reaction against mutant 
keratinocytes hidden in Blaschko’s lines,10 thought to be caused 
in lichen striatus by infectious, mechanical or immunologic fac-
tors. It might be argued that the observed complete remission 
of LS in our patient may be due to the spontaneous healing 
of this dermatosis rather than to the pharmacological action 
of imiquimod. Although this possibility cannot be definitely 
ruled out, it seems, however, very unlikely in view of the rapid 
response and the complete disappearance of the skin lesions 
soon after the onset of treatment.
FIguRe 2. Histological aspect of lichen striatus (hematoxylin-
eosin ×400).
FIguRe 1. Clinical aspect of lichen striatus prior to (A) and after 2 weeks (B) and 5 weeks (C) of topical treatment with 5% im-
iquimod cream.
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Our findings suggest that topical imiquimod may be an 
effective and safe alternative treatment for lichen striatus. 
Further placebo-controlled, randomized clinical trials are now 
warranted to define the efficacy and safety of this compound 
in the treatment of recalcitrant, persistent and relapsing cases 
of lichen striatus.
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